CTOs on the Move

AnHeart Therapeutics

www.anhearttherapeutics.com

 
AnHeart is a clinical stage global biopharmaceutical company developing novel precision oncology therapeutics. Its lead candidate, taletrectinib, is a next-generation ROS1 and NTRK inhibitor currently in Phase 2 trials in first and second-line non-small cell lung cancer (NSCLC). AnHeart is developing a broad pipeline of next-generation precision oncology therapeutics in areas of high unmet medical need.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Biomet Microfixation

Founded by Walter Lorenz more than thirty years ago, Biomet Microfixation manufactures a complete range of craniomaxillofacial products, including LactoSorb, the first completely resorbable fixation system available in the U.S. Other products include

IMV technologies USA

The IMV Technologies Group is a leader in the areas of animal and human assisted reproduction technologies and veterinary imaging. IMV Technologies provides customers with solutions for animal artificial insemination; its human division, Cryo Bio System, offers solutions for human assisted reproduction including human embryo vitrification, human sperm freezing and preservation and other assisted reproduction technologies. The IMV imaging business provides customers with veterinary imaging solutions.

Acureon Pharmaceuticals

Acureon Pharmaceuticals is a Berwyn, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Integrated Genomics Inc

Integrated Genomics Inc is a Arlington Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GLSA | Global Life Sciences Alliance

Global Life Sciences Alliance (GLSA) is a dynamic and collaborative network of global CROs and clinical research vendors specializing in innovative solutions for Sponsors and CROs.The GLSA Team and Network accelerates clinical research timelines through innovation, leveraging extensive experience to foster collaboration and deliver superior outcomes. By mitigating the risks of vendor selection, GLSA ensures exceptional results for clinical trials.